DUBLIN, April 29, 2022–(BUSINESS WIRE)–“Chronic Spontaneous Urticaria (CSU) – Epidemiological Forecast – 2032” drug pipelines added to from ResearchAndMarkets.com offer.

This “Chronic Spontaneous Urticaria – Epidemiology Forecast to 2032” report provides an in-depth understanding of chronic spontaneous urticaria, historical and projected epidemiology in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Currently, many clinical trials are underway on chronic spontaneous urticaria. Ligelizumab from Novartis, an anti-IgE monoclonal antibody, showed superior efficacy to Omalizumab in phase 2b and is currently being evaluated in a phase 3 trial. Dupixent (dupilumab) from Sanofi and Regeneron, already approved in atopic dermatitis, is being evaluated in phase III for chronic spontaneous urticaria. Various other emerging drugs in various phases of trials are rilzabrutinib (Sanofi/Regeneron), remibrutinib (Novartis), benralizumab (AstraZeneca), fenebrutinib (Genentech), KPL-716 (Kiniksa Pharma), UB- 221 (United BioPharma), mepolizumab (GlaxoSmithKline), AK002 (Allakos).

However, there are still few unmet needs in understanding disease etiology in cases where autoimmunity is ruled out. Quality of life is severely affected in patients with chronic spontaneous urticaria due to the unpredictability of attacks, fatigue caused by treatment side effects, and cosmetic disfigurement.

Patients with chronic spontaneous urticaria often present with psychiatric comorbidities. Chronic spontaneous urticaria also has a significant direct and indirect economic impact due to increased health care costs due to continued medication to control symptoms and frequent and often unscheduled medical visits.

Epidemiology of chronic spontaneous urticaria

The Chronic Spontaneous Urticaria Epidemiology Division provides information on the historical and current patient base and projected trend for each of the seven major countries. It helps to recognize the causes of current and predicted trends by exploring numerous studies and insights from key opinion leaders. This part of the report also provides the pool of diagnosed patients and their trends as well as the assumptions made.

The story continues

Main findings

The disease epidemiology covered in the report provides historical and predicted epidemiology of chronic spontaneous urticaria segmented into total number of prevalent cases of chronic spontaneous urticaria, sex-specific cases of chronic spontaneous urticaria and specific cases at the age of chronic spontaneous urticaria. The report includes the widespread scenario of chronic spontaneous urticaria in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain and United Kingdom) and Japan from 2019 to 2032.

Epidemiology of Chronic Spontaneous Urticaria Wise-Chronic

The epidemiology segment also provides epidemiological data and results of chronic spontaneous urticaria in the United States, EU5 (Germany, France, Italy, Spain and United Kingdom) and Japan.

The total prevalent population of associated chronic spontaneous urticaria in 7MM countries was estimated to be 1,848,622 cases in 2021 and is projected to increase at a CAGR of 0.33% for the study period i.e. 2019-2032.

Among EU5 countries, Germany had the highest prevalence of chronic spontaneous urticaria. On the other hand, Spain had the lowest population. In 7MM, Spain had the lowest number of cases at 178,389 cases in 2021.

Report scope

• Chronic Spontaneous Urticaria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment regimens

• The Chronic Spontaneous Urticaria Epidemiology Report and Model provides an overview of global chronic spontaneous urticaria risk factors and trends across the top seven markets (7MM: US, France, Germany, Italy, Spain , UK and Japan)

• The report provides an overview of the historical and forecast chronic spontaneous urticaria patient base in the seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, United Kingdom) and Japan.

• The report helps to recognize growth opportunities in 7MM regarding patient population

• Report assesses risk and burden of disease and highlights unmet needs of chronic spontaneous urticaria

• The report provides the segmentation of chronic spontaneous urticaria epidemiology by prevalent cases of chronic spontaneous urticaria in 7MM

• The report provides the segmentation of total prevalent cases of chronic spontaneous urticaria, gender specific cases of chronic spontaneous urticaria and age specific cases of chronic spontaneous urticaria in 7MM

Main topics covered:

1. Key information

2. Presentation of the report

3. Chronic Spontaneous Urticaria Market Overview at a Glance

3.1. Market share (%) Breakdown of Chronic Spontaneous Urticaria in 2019

3.2. Market share (%) Breakdown of Chronic Spontaneous Urticaria in 2032

4. Executive Summary of Chronic Spontaneous Urticaria

5. Background and overview of the disease

5.1. Introduction

5.2. Signs and symptoms

5.3. Classification

5.4. causes

5.5. Pathophysiology

5.6. Clinical manifestation

5.7. Diagnostic

6. Epidemiology and patient population

6.1. Main findings

6.2. 7MM Total population of patients with chronic spontaneous urticaria

6.3. United States

6.3.1. Assumption and rationale

6.3.2. Total prevalent cases of chronic spontaneous urticaria in the United States

6.3.3. Sex-specific cases of chronic spontaneous urticaria in the United States

6.3.4. Age-specific cases of chronic spontaneous urticaria in the United States

6.4. EU5

6.5. Japan

7. Processing and management

7.1. Treatment and management

7.2. EAACI/GALEN/EDF/WAO directive

8. Appendix

For more information about this Drug Pipelines report, visit https://www.researchandmarkets.com/r/emcdvv

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220429005299/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900